Potential predictive factors of positive prostate biopsy in the Japanese population

International Urology and Nephrology

Volumn 40, Issue 1, 2008, Pages 91-96

  Shigemura, Katsumi ^a,b   Arakawa, Soichi ^b   Yamanaka, Kunito ^a   Yasui, Nobuo ^a   Matsubara, Shigeji ^a   Iwamoto, Takahiro ^a   Kataoka, Nobuo ^a   Yuien, Keiji ^a   Fujisawa, Masato ^b  

^a Nishiwaki Municipal Hospital   (Japan)

^b KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Predictive factor for positive prostate biopsy; Prostate biopsy; Prostate volume

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGE; AGED; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; DIGITAL RECTAL EXAMINATION; HUMAN; HUMAN TISSUE; INFORMATION PROCESSING; JAPANESE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PREDICTION; PROSTATE BIOPSY; PROSTATE CANCER; PROTEIN BLOOD LEVEL; TRANSRECTAL ULTRASONOGRAPHY;

ADULT; AGED; AGED, 80 AND OVER; BIOPSY, NEEDLE; HUMANS; JAPAN; MALE; MASS SCREENING; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSTATE; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC;

EID: 41549162952     PISSN: 03011623     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11255-007-9219-5     Document Type: Article

References (25)

1. Howe HL, Wingo PA, Thun MJ et al (2001) Annual report to the nation on the status of cancer (1973 through 1998), featuring cancers with recent increasing trends. J Natl Cancer Inst 93:824-842
2. Catalona WJ, Smith DS, Ratliff TL et al (1991) Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 324:1156-1161
3. Tsukuma H, Kitagawa T, Hanai A et al (1992) Incidence of cancer: prediction in Japan up to the year 2015. Jpn J Cancer Clin 38:1-10
4. Shibata A, Ma J, Whittemore AS et al (1998) Prostate cancer incidence and mortality in the United States and the United Kingdom. J Natl Cancer Inst 90:1230-1231
5. Schroder FH, van der Cruijsen-Koeter I, de Koning HJ et al (2000) Prostate cancer detection at low prostate specific antigen. J Urol 163:806-812
6. Prorok PC, Andriole GL, Bresalier RS et al (2000) Design of the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial. Control Clin Trials 21:273S-309S
7. Catalona WJ, Richie JP, Ahmann FR et al (1994) Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: Results of a multicenter clinical trial of 6630 men. J Urol 151:1283-1290
8. Catalona WJ, Partin AW, Slawin KM et al (1998) Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: A prospective multicenter clinical trial. JAMA 279:1542-1547
9. Roobol MJ, Zappa M, Maattanen L et al (2007) The value of different screening tests in predicting prostate biopsy outcome in screening for prostate cancer data from a multicenter study (ERSPC). Prostate 67(4):439-446
10. Kamoi K, Babaian RJ (1999) Advances in the application of prostate-specific antigen in the detection of early-stage prostate cancer. Semin Oncol 26:140-149
11. Rodriguez LV, Terris MK (1998) Risks and complications of transrectal ultrasound guided prostate needle biopsy: A prospective study and review of the literature. J Urol 160:2115-2120
12. Eastham JA, May R, Robertson JL et al (1999) Development of a nomogram that predicts the probability of a positive prostate biopsy in men with an abnormal digital rectal examination and a prostate-specific antigen between 0 and 4 ng/ml. Urology 54:709-713
13. Scattoni V, Sangalli M, Roscigno M et al (2005) Detection and diagnosis of prostate cancer: What's new? Arch Ital Urol Androl 77:173-179
14. Ohori M, Swindle P (2002) Nomograms and instruments for the initial prostate evaluation: The ability to estimate the likelihood of identifying prostate cancer. Semin Urol Oncol 20:116-122
15. Carlson GD, Calvanese CB, Partin AW (1998) An algorithm combining age, total prostate-specific antigen (PSA), and percent free PSA to predict prostate cancer: Results on 4298 cases. Urology 52:455-461
16. Brawer MK, Chetner MP, Beatie J et al (1992) Screening for prostatic carcinoma with prostate specific antigen. J Urol 147:841-845
17. Kakehi Y (2003) Watchful waiting as a treatment option for localized prostate cancer in the PSA era. Jpn J Clin Oncol 33:1-5
18. Tsutahar K, Yokoyama S, Fukuhara S et al (2006) Mass screening for prostate cancer in Ikeda City Osaka. Nippon Hinyokika Gakkai Zasshi 97:791-795
19. Tokunaga M, Yasuda M, Miyakita H et al (2005) Screening program of prostate cancer at Tokai University Hospital: Characterization of prostate-specific antigen measurement. Tokai J Exp Clin Med 30:103-110
20. Elabbady AA, Khedr MM (2006) Extended 12-core prostate biopsy increases both the detection of prostate cancer and the accuracy of Gleason score. Eur Urol 49:49-53
21. Kobayashi T, Nishizawa K, Ogura K et al (2004) Detection of prostate cancer in men with prostate-specific antigen levels of 2.0 to 4.0 ng/ml equivalent to that in men with 4.1 to 10.0 ng/ml in a Japanese population. Urology 63:727-731
22. Bozeman CB, Carver BS, Caldito G et al (2005) Prostate cancer in patients with an abnormal digital rectal examination and serum prostate-specific antigen less than 4.0 ng/ml. Urology 66:803-807
23. Garzotto M, Hudson RG, Peters L et al (2003) Predictive modeling for the presence of prostate carcinoma using clinical, laboratory, and ultrasound parameters in patients with prostate specific antigen levels < or =10 ng/ml. Cancer 98:1417-1422
24. Landis SH, Murray T, Bolden S et al (1998) Cancer statistics, 1998. CA Cancer J Clin 48:6-29
25. Landis SH, Murray T, Bolden S et al (1998) Cancer statistics, 1999. CA Cancer J Clin 49:8-31, 1